CRLX101: Phase Ib started

Cerulean began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate weekly IV CRLX101 alone or with IV Avastin bevacizumab in up to 36 patients. Cerulean has exclusive, worldwide rights to...